GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$150.11
−0.52%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- $2.15
- Revenue estimate
- $7.8B
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$6.75
- EPS estimate
- -$7.25
- Revenue actual
- $7.8B
- Revenue estimate
- $7.4B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.9%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $152
- PT range
- $123 – $175
- Analysts
- 9
6 Buy3 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$7.25 | -$6.75 | Beat 6.90% | $7.8B |
| May 7, 2026 | $1.91 | $2.03 | Beat 6.28% | $7.0B |
| Oct 30, 2025 | $2.13 | $2.47 | Beat 15.96% | $7.8B |
| Aug 7, 2025 | $1.96 | $2.01 | Beat 2.55% | $7.1B |
| Apr 24, 2025 | $1.78 | $1.81 | Beat 1.69% | $6.7B |
| Feb 11, 2025 | $1.74 | $1.90 | Beat 9.20% | $7.6B |
| Aug 8, 2024 | $1.61 | $2.01 | Beat 24.84% | $6.9B |
| Apr 25, 2024 | -$1.49 | -$1.32 | Beat 11.41% | $6.7B |
| Aug 3, 2023 | $1.60 | $1.34 | Miss -16.04% | $6.6B |
| Apr 27, 2023 | $1.64 | $1.37 | Miss -16.46% | $6.4B |
| Feb 2, 2023 | $1.48 | $1.67 | Beat 12.84% | $7.4B |
| Oct 27, 2022 | $1.44 | $1.90 | Beat 31.94% | $7.0B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026